NR1H4 and metabolic dysfunction-associated steatohepatitis: Although multiple FXR agonists have demonstrated histologic improvements in preclinical models of NASH, and OCA has demonstrated antifibrotic activity in a phase 3 study of patients with NASH who had precirrhotic liver fibrosis [11], no data are available about the effects of INT-787 in this regard.